1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Lymphoma, B-Cell in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balkin, ER; Jia, F; Lewis, MR; Liu, D; Miller, WH; Ruthengael, VC; Shaffer, SM | 1 |
| Abbas, N; Bruland, ØS; Dahle, J; Larsen, RH; Repetto-Llamazares, A | 1 |
| Arksey, N; Chin, FT; Gambhir, SS; Iagaru, A; Natarajan, A | 1 |
| Buchegger, F; Chyan, MK; Hamlin, DK; Lin, Y; Pagel, JM; Pantelias, A; Park, SI; Press, OW; Shenoi, J; Wan, F; Wilbur, DS; Wilbur, SM | 1 |
| Campana, B; Forrer, F; Lohri, A; Maecke, H; Mueller-Brand, J; Oechslin-Oberholzer, C | 1 |
| Fisher, DR; Goldenberg, DM; Govindan, SV; Griffiths, GL; Sharkey, RM | 1 |
| Axworthy, D; Gopal, AK; Hamlin, DK; Hedin, N; Lin, Y; Pagel, JM; Pantelias, A; Press, OW; Saganic, L; Wilbur, DS; Wilbur, S | 1 |
| Reilly, RM | 1 |
| Antczak, C; Brentjens, R; Chattopadhyay, D; Jaggi, JS; Kappel, BJ; McDevitt, MR; Njardarson, JT; Scheinberg, DA; Schiffman, SR | 1 |
1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Lymphoma, B-Cell
| Article | Year |
|---|---|
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rituximab; Treatment Outcome | 2012 |
8 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Lymphoma, B-Cell
| Article | Year |
|---|---|
Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Genes, bcl-2; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lutetium; Lymphoma, B-Cell; Mice; Oligoribonucleotides, Antisense; Peptide Nucleic Acids; Peptides, Cyclic; Proto-Oncogene Mas; Radioisotopes; Radiometry; Tissue Distribution | 2014 |
Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunotoxins; Iodine Radioisotopes; Lutetium; Lymphoma, B-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Tetraspanins; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Copper Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Transgenic; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed | 2015 |
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Topics: Acetylgalactosamine; Animals; Antigens, CD20; Biotin; Cell Line, Tumor; Chelating Agents; Drug Design; Heterocyclic Compounds, 1-Ring; Humans; Lymphoma, B-Cell; Mice; Molecular Structure; Mutation; Recombinant Fusion Proteins; Single-Chain Antibodies; Streptavidin; Xenograft Model Antitumor Assays | 2010 |
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Isotope Labeling; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2003 |
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Topics: Animals; Antibodies; Antigens, CD; Antigens, CD20; Cell Line, Tumor; Chelating Agents; Drug Delivery Systems; Female; Flow Cytometry; Heterocyclic Compounds, 1-Ring; HLA-DR Antigens; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Mice; Mice, Nude; Radioimmunotherapy; Sialic Acid Binding Ig-like Lectin 2; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine.
Topics: Antibodies; Cell Membrane Permeability; Chelating Agents; Drug Delivery Systems; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Nanotubes, Carbon; Neoplasms; Radioimmunotherapy; Radiopharmaceuticals | 2007 |
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cell Line, Tumor; Chelating Agents; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, SCID; Nanotubes, Carbon; Neoplasm Transplantation; Radiopharmaceuticals; Rituximab; Solubility; Transplantation, Heterologous | 2007 |